Assessing Market Opportunities in Contract Biologics Manufacturing - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Assessing Market Opportunities in Contract Biologics Manufacturing
Strong growth in biopharmaceuticals bodes well for contract manufacturing, but the perils and the promises of pipelines remain.


Pharmaceutical Technology
Volume 33, Issue 5, pp. 56-60

References

1. P. Van Arnum, "Charting API Market Growth and Opportunity." Pharm. Technol. 32 (7), 58–61 (2008).

2. P. Van Arnum, "Global Pharmaceutical Growth Tempered by Lagging US Market," Pharm. Technol. Sourcing and Management , Nov. 2008, http://PharmTech.com/, accessed Apr. 13, 2009.

3. E. Langer, 6th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production , BioPlan Associates (Rockville, MD, Apr. 2009).

4. E. Polastro, "Custom Synthesis and Custom Chemicals," Pharm. Technol . 30 "Outsourcing Resources" supp., 42–66 (2006).

5. P. Van Arnum, "Outlook for Custom Manufacturing Is Mixed," Pharm. Technol. Sourcing and Management , Mar. 2009, http://PharmTech.com/, accessed Apr. 13, 2009.

6. E. Langer, Advances in Biopharmaceutical Technology in China , BioPlan Associates (Rockville, MD, 2007).

7. E. Langer, Top 60 Biopharmaceutical Manufacturers in India , BioPlan Associates (Rockville, MD, Nov. 2008).

8. E. Langer, Advances in Biopharmaceutical Technology in India , BioPlan Associates (Rockville, MD, 2007).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here